Table 2.
Histological features of renal biopsies at D0, D15-D30, M3 and M12.
| D0 (n = 43) | D15-D30 (n = 20) | M3 (n = 28) | M12 (n = 28) | p value | |
|---|---|---|---|---|---|
| Acute lesions: | |||||
| Glomerulitis « g » | 0 ± 0 | 0.2 ± 0.4 | 0.08 ± 0.3 | 0.07 ± 0.3 | 0.12 |
| Peritubular capillaritis « ptc » | 0 ± 0 | 0.1 ± 0.3 | 0.08 ± 0.3 | 0.04 ± 0.2 | 0.41 |
| Interstitial inflammation « i » | 0 ± 0 | 0.2 ± 0.7 | 0.3 ± 0.5 | 0.07 ± 0.3 | 0.01 |
| Total inflammation « ti » | 0.1 ± 0.3 | 0.2 ± 0.7 | 0.6 ± 0.8 | 0.8 ± 0.8 | <0.001 |
| Tubulitis « t » | 0 ± 0 | 0.2 ± 0.7 | 0.2 ± 0.4 | 0.1 ± 0.4 | 0.03 |
| Intimal arteritis « v » | 0 ± 0 | 0 ± 0 | 0.04 ± 0.2 | 0.04 ± 0.2 | 0.54 |
| Acute tubular injury (%) | 63 ± 28 | 47 ± 22 | 9 ± 11 | 4 ± 6 | <0.05 |
| Chronic lesions: | |||||
| Sclerotic glomeruli | 3.5 ± 5.1 | 2.0 ± 3.5 | 4.4 ± 6.7 | 9.0 ± 14.0 | 0.11 |
| Allograft glomerulopathy « cg » | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0.04 ± 0.2 | 0.37 |
| Mesangial matrix increase « mm » | 0 ± 0 | 0 ± 0 | 0.1 ± 0.3 | 0.2 ± 0.5 | 0.01 |
| Interstitial fibrosis « ci » | 0.6 ± 0.5 | 0.7 ± 0.6 | 1.5 ± 0.8 | 1.7 ± 0.9 | <0.001 |
| Tubular atrophy « ct » | 0.2 ± 0.5 | 0.4 ± 0.5 | 1.2 ± 0.8 | 1.5 ± 0.9 | <0.001 |
| Vascular fibrous intimal thickening « cv » | 0.3 ± 0.5 | 0.8 ± 0.9 | 1.0 ± 1.1 | 0.7 ± 0.9 | <0.01 |
| Arteriolar hyaline thickening « ah » | 0.3 ± 0.5 | 0.2 ± 0.4 | 0.4 ± 0.6 | 0.4 ± 0.6 | 0.49 |
| C4d (immunofluorescence): | |||||
| Negative (0 or minimal 1) | 37/37(100%)a | 15/17(88%)b | 24/25(96%)b | 25/26(96%)c | 0.22 |
| Positive (focal 2 or diffuse 3) | 0/37(0%)a | 2/17(12%)b | 1/25(4%)b | 1/26(4%)c | 0.22 |
| Rejection: | |||||
| Antibody-mediated rejection (n) | NA | 2d | 1e | 1e | |
| Borderline rejection (n) | NA | 0 | 4 | 3 | |
| T-cell-mediated rejection (n) | NA | 1 f | 0 | 1 g | |
| Other lesions: | |||||
Digital data are means ± standard deviation.
aNA = 6.
bNA = 3.
cNA = 2.
dAntibody-mediated rejection included: 1 acute antibody-mediated rejection, and 1 “suspicious” for acute antibody-mediated rejection.
eacute antibody-mediated rejection.
fgrade Ib.
gchronic T-cell mediated rejection.